SansRosa Treatment
-- First Topical to Address Erythema & Flushing
SansRosa
Pharmaceutical Development Inc. has received $250,000 from Bioadvance
to fund the first topical rosacea treatment for facial redness and
flushing. San Rosa's first product is a novel treatment for rosacea
that will represent a breakthrough as the first effective therapy
for Subtype I rosacea sufferers. It is a new form of a compound
previously approved for a different inflammatory skin disorder.
The product, designated SR101, when applied topically to rosacea
skin eliminates skin redness rapidly restoring normal skin color.
SR101 will be a topical, once-a-day, rapid onset product that will
minimize the possibility of side effects from systemic administration.
The therapeutic potential of this compound has been documented in
an initial pilot study initiated by an investigator at the Mayo
Clinic This product is in Phase I Clinical Development for rosacea.
So far, the results have shown great promise.
- Interview with Dr. Gary Kurtzman -- Chief Investigative
Officer of Rosacea Treatment
- Interview with Dr. Hal Brodenson -- Chief Investigator
of Rosacea Treatment
- SansRosa's Proposed Mechanism of Action on Rosacea
Erythema
Intoduction
Based on early reports
from the Research and Development sector, it is suggested that the
main ingredient used to reduce rosacea redness will be a phenylephrine
agonist derivative -- similar to the phenyephrine constrictor
drops you find for red eye and the phenylephrine based hemmorhoidal
gel. However, using advanced tecnhology they will only be
using certain phenylephrine alpha (1) receptor agonists to selectively
activate certain receptors to ensure that the rebound phenomenon
does not occur.
To explain, phenylephrine
alpha (1) receptor agonists act on four different receptors in blood
vessels to cause constriction. Two receptors are known to
be the main culprits in the rebound phenomenon; while the other
two are good constrictors, but do not show the tendency towards
rebound vasodilation. The four agonists are:
- Phenylephrine alpha (1A) agonist
- Phenylephrine alpha (1B) agonist
- Phenylephrine alpha (1C) agonist
- Phenylephrine alpha (1D) agonist
The ones that do not cause
the rebound phenomenon are:
- Phenylephrine alpha (1B) agonist
- Phenylephrine alpha (1D) agonist
These agonists cause gentle
constiction of blood vessels which results in reduced facial redess
and attenuation of flushing tiggers without altering oxygen levels
or nutrient delivery.
Special Time-Released
Liposomal Hydrogel Delivery System for Fast Release and 24 Hour
Sustained Release
Reports also indicate
that the action on blood vessels will take place immediately and
be long lasting (24 hours) which should be of great benefit to rosacea
sufferers. The special time-released liposomes will
release 25% of the active drug immediately when it is activated
by heat from blood vessels and the inner liposomal layer will slowly
release the remaining 75% of the drug over the next 23 hours for
sustained release.
The hydrogel liposomes
are very friendly to skin and melt right through the epidermis without
damaging epidermal cells. Also, the polymer technology allows
the liposomes to penetrate extremely deep so that it should have
an efffect on superficial vessels and medium depth vessels.
Other Active
Ingredients?
It is safe to assume that
the Research and Development team did not tell me everything due
to the competitive market. I was lead to believe there would
be one or two 'secret' complimentary ingredients to enhance the
action of this topical rosacea drug. We most certainly wont
hear the exact details on these until the product is on the market.
This is good news for
rosacea sufferers.
New Information
Sheds Light on SansRosa Anti-Redness Topical
Due to the early stages
of development, companies need to sometimes keep drug information
secret until patents are approved and their drug is safe from other
companies. This does lead to incomplete information sometimes,
especially when it is cutting-edge information presented years before
it will hit the shelves. The only infrormation that I can
reveal is now it seems the main active ingredient is not a phenylephrine
derivative; it is a selective alpha-2 receptor agonist. I
am not sure if it will act on both alpha-2A and alpha-2C receptors,
or just act on one receptor subtype. The alpha-2 receptor agonist
was chosen primarily due to its long history of use in humans and
becuase this group of receptors was the least likely to cause side
effects and rebound dilation. I just wanted to update everyone
with the latest information. This may also help reduce the
symptoms of ocular rosacea, but I dont think that will be a main
focus until the facial skin preparation is available.
